INTRODUCTION

The advent of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has resulted in more than 3,233,845 deaths around the World as on May 6, 2021, and has created an unprecedented healthcare, social and economic disaster.\(^1\,^2\) Recently, the National Institute of Virology (NIV) of India detected a strain of coronavirus with a double mutation named B.1.617 in samples collected from major Indian states having mutations from two separate virus variants, namely E484Q and L452R.\(^3\)

Virus spread can be halted/minimized by protective measures like use of N95 masks, hand sanitizers/washing and by social distancing. But, sometimes despite all the precautions, some people are at a higher risk of contracting this infection including dental professionals due to their close proximity to patients while working and generation of aerosols in most of the dental procedures, and asymptomatic patients pose more risk. Various studies have emphasized the importance of oral health and how the oral cavity is an entry point for numerous viral diseases, including the coronavirus.\(^4\,^5\) Although COVID-19 is considered a disease of respiratory system primarily affecting the lungs, studies have shown that SARS-CoV-2 virus can also invade the oral mucosa and salivary gland epithelium due to high expression of angiotensin converting enzyme 2 (ACE2) receptors at these sites, thereby leading to an
increase in viral load in the oral cavity.\textsuperscript{5,7,8} Keeping in view this concept, it seems logical to curb this virus at the entry point itself. This review mainly focuses on chief antimicrobial ingredients of various nasal and oral rinses that could reduce the viral load in the oral cavity, oro- and nasopharynx. We aim to summarize the information related to antiviral agents acting against SARS-CoV-2 till date and potential ingredients present in oral rinses which could be effective in patients.

SARS-CoV-2 virus belongs to the family of enveloped RNA viruses, \textit{coronaviridae}. The presence of ‘spike protein’ (S protein) on its membrane envelope plays a significant role in the pathogenesis of this disease (Figure 1). This S protein interacts mainly with the ACE2 receptors whose distribution in different parts of oral cavity indicates several virus entry points like non-keratinized mucosa of the mouth, epithelial cells of tongue and salivary glands.\textsuperscript{5} Priming of the virus S protein is carried out with the help of the cellular transmembrane serine protease 2 (TMPRSS2).\textsuperscript{5} Interestingly, individuals with healthy or poor oral hygiene status have reported viral load of SARS-CoV-2 in their saliva.\textsuperscript{5,9,10} This indicates that the oral tissues are a probable reservoir from which the SARS-CoV-2 virus can be transmissible during breathing, coughing, sneezing and talking. Although patients infected with this virus do not require hospitalization very often, the ones with comorbidities are prone to complications such as pneumonia, respiratory failure and multiple organ collapse.\textsuperscript{11} Little is known about how transmission occurs from the oral cavity to the rest of the body causing systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) in severe and fatal cases.\textsuperscript{5} One of the theories can be that it invades through a periodontal pocket, then into the tissues and, finally into the blood stream as it is said that periodontitis seems to worsen the symptoms of COVID-19.\textsuperscript{9} Another theory could be the settling of the virus on the tonsillar crypts and the oropharynx further going into the gastrointestinal tract and cause symptoms like diarrhoea.

Cerebral involvement, considered a deadly form of this disease, is believed to be caused by the cellular receptor neuropilin-1 which binds with furin cleaved substrates forming a path of progression through central nervous system.\textsuperscript{12,13} Hence, a good understanding of its pathogenesis, site of entry, identifying and treating the disease at its earliest course can be useful for saving the humankind from this pandemic (Figures 2 and 3).

One of the striking symptoms which most of the people suffer when infected with COVID-19 is loss of smell seen even in severe allergic rhinitis or after an attack of cold.\textsuperscript{12,14} This could occur as the virus invades and binds to ACE2 receptors which support the nerve cells that detect smell and thereby their inflammation can cause anosmia. Although it is not known as to why there is a loss in taste, it is said that this is the consequence of loss of smell.\textsuperscript{14} Another reason that could be the cause of ageusia is the alterations in protein and substance composition of the saliva. There are many substances in saliva that have affinity to bind with different foods of different taste and it is said that when COVID-19 invades the cells of salivary glands, it can cause alteration either in the composition or in the amount of saliva produced.\textsuperscript{15,16}

Oral rinses or mouthwashes are frequently used for rinsing the teeth, gums, mouth and halitosis, before and after oral surgery/dental procedures because they contain antiseptic agents which help in killing the harmful oral microbes and reduce the microbial load in the aerosols generated during dental procedures.\textsuperscript{17-19} Although there is a lack of evidence if mouthwashes act as effective antiviral agents that will reduce the SARS-CoV-2 transmission, the American Dental Association (ADA) has recommended the usage of preprocedural mouth wash povidone iodine (PVP-I; 0.2%) before any oral procedures for the safety of healthcare professionals and patients.\textsuperscript{17} Due to the surge in COVID-19 cases and its high transmissible rates, researchers have carried \textit{in vitro} studies to test the virucidal activity of common over-the-counter oral antiseptics such as hydrogen peroxide, thymol, cetylpyridinium chloride, chlorhexidine, povidone iodine, essential oils, etc., we aim to focus on antiviral properties, since most of these mouthwashes are known to have antimicrobial properties. The World Health Organization (WHO) has not specified on the use of mouth rinses as a preventive or viral eradication measure in controlling COVID-19 but they have been used in controlling similar type of viral diseases.

2 | MATERIALS AND METHODS

The present review followed the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement guidelines.\textsuperscript{20}

2.1 | Search strategy

The objective of the review was to find the efficacy of oral rinses on virucidal property against n-coronavirus \textit{(in vivo studies)}. Search engines used for this study included Medline (via PubMed), Scopus, Web of Science, EMBASE, CINAHL, Google scholar, Clinical Trial Registry and ProQuest and were searched electronically to retrieve all data using MeSH terms and Boolean operators: ‘mouthwash’ OR ‘oral rinse’ OR ‘mouth rinse’ OR ‘povidone iodine’ OR ‘chlorhexidine chloride’ OR ‘hydrogen peroxide’ OR ‘cetylpyridinium chloride’ OR ‘essential oil’ OR
‘phthalocyanine derivatives’ OR ‘ethanol’ OR ‘citrox’ AND ‘COVID-19’ OR ‘SARS-CoV-2’ OR ‘SARS’. Search strings were developed as appropriate to the different databases.

The search was complemented by hand searching of the reference list of included relevant articles. Articles published from December 2019 to June 2021 were included. Two reviewers (GG & LT) independently searched the databases and screened abstract and title. Third reviewer (SC) resolved the discrepancies between two reviewers. Two reviewers (NU & SC) performed full-text screening and data extraction. Any disagreement between the researchers was resolved by consensus and researcher (considered unbiased) who moderated the research activity.

2.2 | Inclusion criteria

Clinical or in vivo studies that used mouthwashes, a form of intervention as a hypothesis for decreasing the viral load in saliva, were included.

2.3 | Exclusion criteria

1. Studies that evaluated mouthwashes for viruses other than SARS-CoV-2 infected individuals/saliva
2. Studies where the evaluation was carried with ingredients (anti-septic ingredients present in mouthwashes) other than saliva
3. Descriptive studies such as reviews, conference abstracts, expert opinions, chapter in books and case reports.

2.4 | Risk of bias

The risk of bias (RoB) of individual studies was independently assessed by two authors (NU & SC) using the check list presented in Appendix S1. Quality criteria were designated with a positive sign (+) if an informative description was present, a negative sign (-) and if the informative description did not meet the criteria and a question mark (?) if the information was missing or insufficient. A study was classified to be ‘low risk
of bias’ with all positive scores, assigned to criteria of random allocation, defined inclusion/exclusion criteria, blinding to product and examiner, identical treatment between groups and reporting of follow-up. When two or more of these criteria were missing, the study was considered to have a high potential risk of bias.21 The data were extracted using a data extraction sheet which included name of the first author, title, year of publication, country, study design, age and gender, sample size, type of intervention and control, time of testing the viral load, method of testing, bio-efficacy rate, statistical test used and limitation.

3 | RESULTS

The total number of articles from various databases were as follows: PubMed: 278, Scopus: 178, Web of Science: 363, EMBASE: 608, Google scholar: 705, ProQuest: 193, CINAHL: 60, Clinical Trial Registry: 34 and hand searching (of included studies): 19. From 2438 articles, 905 remained after removing the duplicates. After a thorough screening process, 12 articles were eligible to be included in this review (Figure 4). Five studies identified for inclusion in the review were non-randomized in vivo studies with small sample size (Table 1, Clinical heterogeneity). Furthermore, it was observed in all RCTs (Table 2, online Appendix S1 and S2), although PVP-I was found to be efficient, the percentage and the time interval taken to test the efficacy against this virus was not consistent (methodological heterogeneity).22-24 Chlorhexidine (CHX) as a combination of mouth rinse and oropharyngeal spray was found to be more effective than mouth rinse alone; cetylpyridinium chloride (CPC) did show promising results (Table 2). The summary on the potential RoB estimated on various studies, as presented in the online Appendix S1, estimates high RoB in all study.23-28 A study related to oral rinse PVP-I reported thyroid dysfunction in 42% of their patients, the symptoms resolved following treatment discontinuation.26

4 | DISCUSSION

Hydrogen peroxide (H₂O₂): is a widely used antimicrobial agent and studies have been conducted to demonstrate its effect on several viruses including SARS-CoV-2 and influenza. The oral microbiota produce H₂O₂ physiologically and maintain a balance of oral microenvironment and it act on the epithelial cells that contain an enzyme, superoxide dismutase which catalyses the reaction converting H₂O₂ into ion superoxide. This oxidative stress activates NF-κβ, leading to a local innate response that plays a major role in regulating host immune system and acting against viral infections.8 So, it was proposed that washing nose, mouth and throat with H₂O₂ may improve local innate responses to SARS-CoV-2 virus and increase protection against COVID-19 disease.

In vitro studies have been done to test the action of H₂O₂ against SARS-CoV-2 virus or just its S protein.22-26,29 A corona surrogate, transmissible gastroenteritis virus (TGEV), was dried on stainless steel to H₂O₂ vapour (20 µl) for 2–3 h and was seen that about 5log10 reduction in viral load. This study proved H₂O₂ to have good surface decontamination ability, but concerns were on relative susceptibility of viruses in vivo and safety dosage when used as oral/nasal rinse.30 On the contrary, an in vivo study on 12 COVID-19 patients instructed to gargle mouth and throat with 20 ml of 1% H₂O₂ for 30 s with a repeat RTPCR test after 30 min concluded no significant reduction in oral viral load and its use was questionable.22,23 More in vivo studies would give a clear scientific background of the use of this rinse.

Povidone iodine (PVP-I): is composed of water-soluble polymer and polyvinyl pyrrolidone that acts as an antimicrobial agent which dissociates to release iodine, disrupting the membrane protein of microbes and is used as an antiseptic for skin disinfection before and after surgery.8 Usually used topically, with the outbreak of COVID-19, its usage both nasally and orally was suggested by many frontline workers and researchers.31,32 Pelletier et al.31 reported the first anti-SARS-CoV-2 estimation of a nasal antiseptic and an oral rinse antiseptic containing PVP-I, which have been developed specifically for routine intranasal or oral use. Many authors have recommended the use of 0.5%–1% of PVP-I as mouth rinse for 30–60 s.33-38 It has a good virucidal activity as confirmed by real-time reverse PCR (rRTPCR).37 The viral load of SARS-CoV-2 is as high in asymptomatic patients as those with symptoms and inactivation of this virus has been documented to a usage of 0.5% PVP-I for 15 s.26,39 PVP-I is said to be safe with a concentration of up to 2.5% intraorally up to 5 months as it also maintains

![Figure 4 PRISMA flow diagram showing the process of surveying, screening and selecting the articles for systematic review (December 2019 to June 2021)](image-url)
TABLE 1  Evidence-based non-randomized in vivo studies on efficacy of oral rinses against SARS-CoV-2

| Intervention                        | Biological efficacy                                      | Limitations                                                      | References               |
|-------------------------------------|----------------------------------------------------------|------------------------------------------------------------------|--------------------------|
| Hydrogen peroxide (1%)              | No significant reduction in viral load                   | Small sample size, different concentrations and contact times were not measured, no control group | Gottsauner et al. 202022 |
| Povidone iodine (1%)                | Viral load decreases transiently for 3 h                 | Small sample size, no control group                              | Martínez et al. 202033   |
| Chlorhexidine (0.12%)               | Viral load decreases transiently for 2 h after mouthwash, but increased again at 2–4 h post-mouthwash | Small sample size, absence of negative control, pts were on intraoral viral therapy, no control group | Yoon et al. 20206        |
| Phthalocyanine derivate (5 ml)      | Reduction in clinical symptoms                           | Small sample size, no control group                              | da Fonseca et al. 202153 |
| Chlorhexidine (0.2%) and Chlorine dioxide (0.1%) | Reduction in clinical symptoms                           | No control group                                                 | Avhad et al. 202044      |

the oral ecosystem.40,41 ADA has advised mouth rinse of PVP-I 0.2%, while the amount of PVP-I ranged from 0.3 ml (nasal) to 9 ml (mouth rinse and gargling). However, its use is contraindicated in patients with allergy to iodine, thyroid disease and pregnancy.42 Recently, it has been proposed that a minimum of 0.23% concentration of PVP-I for at least 15 s before any procedure is effective in decreasing viral load, and hence has been indicated in COVID-19-positive patients.43

Chlorhexidine (CHX): is a broad-spectrum antiseptic, acts primarily against lipid-enveloped viruses and so there is a high possibility that it may act against enveloped coronaviruses.8 A review by Bernstein et al.27 stated that CHX usage reduces viral transmission through aerosol generation but its action still remains debatable.6 CHX (0.12%) of 15 ml decreased the viral load 2 h post-rinse; however, viral load increased again: the challenge faced in the study was a small sample size and changes were also observed with reduction in clinical signs and symptoms.6,44 A RCT by Huang also proves the efficacy of CHX (0.12%) for 30 s twice daily.45 Similar findings at same concentration for 60 s were proved by few researchers.46,47 Hence, more studies are required to understand the efficacy of this mouthwash.

Cetylpyridinium chloride (CPC): is a quaternary ammonium compound having a broad antimicrobial activity, primarily on gram-positive bacteria. It has a lysozyme-like action and is able to destroy viral capsids.48 It also shows a fungicidal effect on yeasts. As CPC is an antimicrobial, antiviral and antifungal agent, it was thought that it might have an action against enveloped viruses too, such as coronavirus.8 This compound has been regarded as safe by Food Drug Administration and has the ability to act against SARS-CoV-2 virus.49 A RCT concluded that salivary viral load decreased significantly with PVP-I and CPC mouth rinses at 6 h and a similar type of study has proved its efficacy against the virus.27,50 Even a long-term use of CPC (around 6 weeks) does not disrupt the equilibrium of oral microbiota.35,56 A combination of CPC (0.075%) and zinc lactate (0.28%) proves its efficacy in saliva up to 60 min after rinsing.46 Since just a handful of studies are available with respect to (w.r.t) CPC and its action against coronavirus, this is an area of research that has a lot of potential to be explored. Long-term use of these mouth washes needs to be monitored.

4.1  | Excipients in oral rinses

Ethanol is a common excipient used in several oral rinses and has been observed as an effective agent against SARS-CoV-2 virus. It acts by attacking the lipid membrane of the micro-organisms, denatures proteins and lipid structure. It primarily inactivates enveloped virus at a higher concentration than what is deemed safe for oral use and is added in lower concentrations in many mouthwashes (14–27% weight/volume).27,51,52 Bidra et al.26 reported that use of 70% of ethanol for 30 s inactivated SARS-CoV-2 virus. Studies are required to standardize the use of non-toxic concentrations of ethanol which will inactivate SARS-CoV-2 virus. Therefore, in vitro and in vivo studies should be carried out in order to define its role against SARS-CoV-2 prior to its use in oral and nasal rinses.

Combos of antimicrobial and antiviral agents: are also being tested so as to have a more effective bactericidal and virucidal activity owing to a cumulative effect of such combinations. Most of the mouthwashes are alcohol based owing to increased antibacterial and antiviral activity. Precautions need to be taken with usage of alcohol-based rinses in vulnerable groups (children, pregnant women and people with previous alcohol addiction). CHX 0.06%, sodium fluoride (NaF, 0.025%) and CPC 0.03% proved to be effective as non-alcohol-based oral rinses.52 We believe that such combinations should be used and their activity should even be tested against SARS-CoV-2 virus too.

4.2  | Phthalocyanine derivate

A study by de Fonseca et al.53 indicated that a phthalocyanine derivate-based mouthwash shows promising action in reducing SARS-CoV-2 viral load. Five millilitre of phthalocyanine derivate mouthwash for 1 min, five times daily for 2 weeks, reduced the clinical symptoms of the disease. The limitations of this study is a small sample size, lack of control group and the fact that lack of RTPCR test on patients’ salivary samples before and after use of the mouth
### TABLE 2  Evidence-based randomized control trials on efficacy of oral rinses against SARS-CoV-2

| Sample size and Time of testing | Intervention | Biological efficacy | References |
|---------------------------------|--------------|----------------------|------------|
| No. of pts: 61                  | PVP-I (1%) and CHX (0.2%) mouth rinsed for 30 s | Significant difference was noted between the Ct value of distilled water and each of the two solutions. Both are effective in preventing SARS-CoV-2 infection | Elzein et al.36 |
| Saliva samples for RT PCR taken before and after 5 min of applying the intervention | | | |
| No. of pts: 24                  | 25 ml of 1% aqueous PVP-I solution each, followed by 2.5 ml nasal pulverization of the same solution into each nostril using an intranasal mucosal atomization device and a dab of 10% PVP-I ointment over nasal mucosa | Mean relative difference in viral titres between baseline and day 1 was 75% in the intervention group and 32% in the control group. No change in reduction of viral load over 7 days | Guenezan et al.38 |
| Day 1: RT PCR pre-rinse (baseline) followed by 3 h after application of PVP-I (nasal & oral) | | | |
| Day 7: Repeat RT PCR after 3 h application of PVP-I | | | |
| No. of pts: 294                 | CHX (0.12%) used as oral rinse for 30 s twice daily, oropharyngeal spray (1.5 ml) three times per day | Combination was found to be more effective when compared to CHX oral rinse alone | Huang et al.45 |
| RTPCR test was done 4 days post-rinse | | | |
| No. of pts: 40                  | 15 ml of normal saline, 1% hydrogen peroxide, 0.12% CHX or 0.5% PVP-I | All four mouth rinses decreased viral load by 61–89% at 15 min, and by 70–97% at 45 min | Chaudhary PP et al.47 |
| Subjects advised to vigorously rinse with a total of 15 ml (7.5 ml each) at intervals of 30 s each for 60 s. Saliva samples were collected at 15 and 45 min post-rinsing for RT PCR | | | |
| No. of pts: 60                  | Placebo (oral rinsing with distilled water), CPC (0.075%)+Zn (0.28%) group: rinse with 20 ml for 30 s; hydrogen peroxide (1.5%) group: rinse with 10 ml for 1 min; CHX group: rinse with 15 ml for 30 s; hydrogen peroxide+CHX group: rinse with 10 ml of hydrogen peroxide for 1 min, followed by rinsing with 15 ml of CHX for 30 s | CPC+Zinc mouthwash and CHX mouthwash provided a significant reduction in the SARS-CoV-2 viral load up to 60 min after rinsing, while HP provided a significant reduction of up to 30 min after rinsing | Eduardo et al.46 |
| Unstimulated saliva collected at baseline (T0), immediately after rinsing (T1), 30 min after rinsing (T2) and 60 min after rinsing (T3) and subjected to RT PCR analysis | | | |
| No. of pts: 36                  | PVP-I 0.5% (10 ml betadine gargle and mouthwash) CHX 0.2% (peary white Chlor-Rinse) CPC 0.075% (Colgate Plax mouthwash) & sterile water | No significant difference in salivary Ct values within each group at the described intervals. Compared with the water group a significant decrease in the viral load, while a significant decrease in the CPC group at 5 min and 6 h and in the PVP-I group only at 6 h | Seneviratne et al.27 |
| Saliva samples collected at baseline (pre-rinse) & post-rinse (5 min, 3 & 6 h) & subjected to RT PCR analysis | | | |
| No. of pts: 176                 | Placebo or β-cyclodextrin (0.1%) and citrox (0.01%) rinse, 30 ml of mouthwash | Combination of CDCM had a significant beneficial effect on reducing SARS-CoV-2 salivary viral load 4 h after the initial dose. For long-term effect, the benefit to recommend CDMC appears limited | Carrouel F et al.62 |
| Participants were instructed to use mouthwashes three times per day, followed by saliva testing for RT PCR at intervals of T1 (at 09.00 h: before the first mouthwash) and then at T2 (13.00 h) and T3 (18.00 h). Only one sample was taken at 15.00 h on day 6 | | | |

Abbreviations: CDCM: β-cyclodextrin & citrox; CHX: chlorhexidine; CPC: cetylpyridinium chloride; Ct: cycle threshold; PVP-I: povidone iodine.
5 | CONCLUSION

As the COVID-19 second-wave reaches its peak, it has gotten all the more very importance that we ramp up our clinical testing, in vitro and in vivo studies, as we seem to have quite a few positive outcomes in various studies mentioned in this review. Some agents such as EOs and phthalocyanine derivatives seem to aid in reducing the clinical severity of the symptoms, and others like PVP-I, CHX and CPC actually result in reduction in salivary viral load of SARS-CoV-2. As soon as more evidence-based studies and clinical trials prove the safety and efficacy of these agents, they should be put into use as a part of daily routine as well as in healthcare practices to fight this pandemic and future viral infections too. Home remedies have proven to act as a preventive measure and in reducing the severity of clinical symptoms in novel coronavirus-19 disease. Over-the-counter oral rinses, instead of being provided in expensive bottles, should be made available in small sachets for a quick and cost-effective use by the common man. In this difficult time of pandemic, there is a need to make protective measures like hand sanitizers, masks and oral rinses cost-effective, easy to use and readily available at small local stores. It is time that we made a translational step towards a safer clinical practice and community-based prophylactic measures that may help in estimating and controlling the viral load in individuals as well as their transmission within populations.

6 | CLINICAL RELEVANCE

The RCTs of oral rinse/mouthwashes on SARCoV-2 give an evidence-based approach on the use of the antiseptic (PVP-I of 0.5%-1%) having virucidal properties, as a preprocedural rinse such that it will decrease the viral load in both asymptomatic and symptomatic patients, and also in preventing cross-infections between patients and treating dental or medical personnel. As per the occupational safety and health administration guidelines, this mouth rinse is safe and cost-effective, and could also be used as a prophylactic measure in vulnerable population.

ACKNOWLEDGMENT

None.

CONFLICT OF INTEREST

There are no conflicts of interest.

AUTHOR CONTRIBUTIONS

Gargi Gandhi, first author, contributed to the acquisition, analysis and interpretation of data, and drafted the manuscript. Latha Upadhya contributed to the design of study, the acquisition, analysis and interpretation of data, and drafted the manuscript. Nagaraja Thimmappa contributed to the design of study and critically revised the manuscript. Sunitha Carnelio contributed to the conception and design of the study, supported the analysis and interpretation of the data and critically revised the manuscript. All authors gave final
approval and agreed to be accountable for all aspects of this work, ensuring its integrity and accuracy.

ETHICAL STATEMENT
Ethical committee clearance is not required as this is a systematic review based on the published articles.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in [repository name] at [DOI].

ORCID
Gargi Gandhi https://orcid.org/0000-0003-3777-1493
Sunita Carnelo https://orcid.org/0000-0002-2789-3692

REFERENCES
1. WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https://covid19.who.int
2. Koch-Heier J, Hoffmann H, Schindler M, Lusgi A, Planz O. Inactivation of SARS-CoV-2 through treatment with the mouth rinsing solutions ViruProX® and BacterX® Pro. Microorganisms. 2021;9:521.
3. Triple mutation Covid variant in India? Here’s what we know so far. Times of India. https://timesofindia.indiatimes.com/india/triple-mutation-covid-variant-in-india-heres-what-we-know-so-far/articleshow/82183386.cms
4. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9.
5. Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28(1):9.
6. Yoon JG, Yoon J, Song JY, et al. Clinical significance of a high SARS-CoV-2 viral load in the saliva. J Korean Med Sci. 2020;35(20):e195.
7. Cavalcante-Leão BL, de Araujo CM, Basso IB, et al. Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review. J Clin Exp Dent. 2021;13(2):e179-189.
8. Carrouel F, Gonçalves LS, Conte MP, et al. Antiviral activity of reagents in mouth rinses against SARS-CoV-2. J Dent Res. 2021;100(2):124-132.
9. Patel J, Woolley J. Necrotizing periodontal disease: oral manifestation of COVID-19. Oral Dis. 2021;27(3):768-769.
10. Corchuelo J, Ulloa FC. Oral manifestations in a patient with a history of asymptomatic COVID-19: case report. Int J Infect Dis. 2020;100:154-157.
11. Meyers C, Robison R, Milici J, et al. Lowering the transmission and spread of human coronavirus. J Med Virol. 2021;93(3):1605-1612.
12. Rahban C, Allianou A, Jacot E, Landis BN. Anomie et aguesie: é propos d’un cas [Concomitant anosmia and ageusia: a case report]. Rev Med Suisse. 2015;11(488):1787-1790.
13. Cantutti-Castelvetri L, Ojha R, Pedro LD, et al. Neuprolipin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856-860.
14. Cirillo N, Coiella G. Self-reported smell and taste alteration as the sole clinical manifestation of SARS-CoV-2 infection. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;131(4):e95-e97.
15. Zhu Y, Feron G, Von Koskull D, Neiers F, Brignot H, Hummel T. The association between changes of gustatory function and changes of salivary parameters: a pilot study. Clin Otolaryngol. 2021;46(3):538-545.
16. Mahmoud MM, Abouhashish HM, Khairy DA, Bugshan AS, Khan AM, Moodeeth MM. Pathogenesis of dysgeusia in COVID-19 patients: a scoping review. Eur Rev Med Pharmacol Sci. 2021;25(2):1114-1134.
17. Vergara-Buenaventura A, Castro-Ruiz C. Use of mouthwashes against COVID-19 in dentistry. Br J Oral Maxillofac Surg. 2020;58(8):924-927.
18. Testori T, Wang HL, Basso M, et al. COVID-19 and Oral Surgery: a narrative review of preoperative mouth rinses. Acta Stomatol Croat. 2020;54(4):431-441.
19. Reis INR, do Amaral GCLS, Mendoza AAH, et al. Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols? Medical Hypotheses. 2021;146:110436. 10.1016/j.mehy.2020.110436
20. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097.
21. Van Der Weijden GA, Dell’Acqua F, Slot DE. Alveolar bone dimensional changes of post-extraction sockets in humans: a systematic review. J Clin Periodontol. 2009;36(12):1048-1058.
22. Gottausner MJ, Michaelides I, Schmidt B, et al. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig. 2020;24(10):3707-3713.
23. Ortega KL, Rech BO, El Haje GLC, Galbo CB, Pérez-Sayáns M, Braz-Silva PH. Do hydrogen peroxide mouthwashes have a virucidal effect? A Systematic Review. J Hosp Infect. 2020;106(4):657-662.
24. da Mota Santana LA, Andrade Pinho JF, Frank S, Brown SM, Tessema B. Comparison of in vitro inactivation of SARS-CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic rinses. J Prosthodont. 2020;29(7):599-603.
25. Seneviratne CJ, Balan P, Ko KKK, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021;49(2):305-311.
26. Ramalingam S, Graham C, Dove J, Morrice L, Sheikh A. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19. J Glob Health. 2020;10(1):e010332.
27. Sette-de-Souza PH, Soares Martins JC, Martins-de-Barros AV, Rodrigues Vieira B, Fernandes Costa MJ, da Costa Araújo FA. A critical appraisal of evidence in the use of preprocedural mouthwashes to avoid SARS-CoV-2 transmission during oral interventions. Eur Rev Med Pharmacol Sci. 2020;24(19):10222-10224.
28. Capetti AF, Borgonovo F, Morena V, et al. Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers. J Med Virol. 2021;93(3):1766-1769.
29. Pelletier JS, Tessema B, Frank S, Westover JB, Brown SM, Capetti AF. Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Ear Nose Throat J. 2021;100(2):1925-1965.
30. Hassandarvish P, Tiong V, Mohamed NA, et al. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. 2020;2:1-4.
31. Martínez Lamas L, Diz Dios P, Pérez Rodríguez MT, et al. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020. 10.1111/odi.13932.
32. Mateos Moreno MV, Obrador AM, Márquez VA, Ferrer García MD. Oral antiseptics against coronavirus: in vitro and clinical evidence. J Hosp Infect. 2021;113:30-43.
33. Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9(3):669-675.
